Vivozon Pharmaceutical비보존 제약

Vivozon Pharmaceutical is still loss-making on a trailing basis, with revenue shrinking and heavy borrowings, though the share price has risen over the past three months.

Vivozon makes prescription and over-the-counter medicines in Korea and sells through pharmacies and wholesalers. For the twelve months to H1 2026 it reported revenue of ₩50.3B, an operating loss of ₩18.9B and a net loss of ₩32.8B, with borrowings of ₩32.2B against cash of ₩8.7B. The share price closed at ₩2,900 on 2026-10-26, down 43.7% over one year but up 26.1% over three months.

What stands out

• Revenue fell 32.3% in 2025 to ₩59.3B after growth in 2023 and 2024, and the trailing figures show a continued operating loss of about -37.5% margin.
• Free cash flow was negative at about ₩11.5B on a trailing basis, and liabilities are 71.6% of equity.
• Foreign ownership rose from 0.9% to 1.6% over the last 60 days, while retail investors were net sellers over the last 20 days.
• Recent filings are mostly shareholding and holding reports, plus a conversion price adjustment for the 21st series of convertible bonds and the half-year report for June 2026.
• No recent news headlines were provided, so the company's news flow is not visible in this data.

What to watch

• Upcoming results and whether the operating loss narrows from the trailing level of about -37.5% margin.
• Further adjustments to convertible bond conversion prices, which can dilute existing shareholders.
• Debt repayment capacity, given ₩32.2B of borrowings against ₩8.7B of cash and negative free cash flow.